Replimune Group, Inc. reports clinical, regulatory and financial developments for a clinical-stage biotechnology business developing oncolytic immunotherapies for cancer. The company’s proprietary RPx platform uses an engineered HSV-1 backbone intended to promote tumor cell killing, immunogenic cell death and systemic anti-tumor immune responses.
Recurring Replimune news centers on RP1, or vusolimogene oderparepvec, including data from the IGNYTE clinical trial, combination use with nivolumab in advanced melanoma, Biologics License Application activity and FDA complete response letters. Updates also cover RP2 clinical data in advanced solid tumors, scientific presentations at oncology meetings, quarterly financial results, research and development spending, cash runway commentary and management presentations at healthcare conferences.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company located in Woburn, MA, focuses on pioneering tumor-directed oncolytic immunotherapies. On March 15, 2023, the management will present at the Barclays Global Healthcare Conference at 2:05 pm EDT in Miami, FL. They will also hold in-person investor meetings at the Jefferies Biotech on the Bay Summit. Replimune's innovative RPx platform utilizes a potent HSV-1 backbone designed to enhance immunogenic cell death and trigger systemic anti-tumor responses. The dual mechanism of action allows for synergistic effects with various cancer treatment modalities, showcasing its versatile and attractive safety profile.